文献速递胸部肿瘤

阿替利珠单抗联合化疗一线治疗非鳞NSCLC:IMpower132随机III期最终结果

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
PubMed 文献 · J Thorac Oncol · 2020-12-14

IMpower132研究评估阿替利珠单抗联合卡铂或顺铂加培美曲塞(APP)对比单纯化疗(PP)一线治疗无EGFR/ALK突变的IV期非鳞NSCLC。主要终点PFS显著改善(7.6 vs 5.2个月,HR=0.60,P<0.0001),OS数值上倾向APP但未达统计学显著(最终分析17.5 vs 13.6个月,HR=0.86,P=0.1546)。安全性可控。

要点

  • APP方案显著改善PFS,疾病进展风险降低40%。
  • OS在APP组有数值延长但未达统计学显著。
  • 3-4级治疗相关不良事件APP组54.6%,PP组40.1%。

核心结论

  • IMpower132达到PFS主要终点但未达到OS主要终点,APP组OS有数值改善。
  • APP方案安全性可控,未见新的或非预期安全信号。

研究设计与样本

  • 随机III期研究,纳入初治IV期非鳞NSCLC无EGFR/ALK敏感突变患者,1:1随机接受APP或PP方案。
  • 意向治疗人群共578例(APP组292例,PP组286例),每3周给药4或6周期后维持治疗。

主要发现

  • PFS主要分析(2018年5月22日,中位随访14.8个月):APP组中位PFS 7.6个月 vs PP组5.2个月(分层HR=0.60,95%CI 0.49-0.72,P<0.0001)。
  • OS中期分析(2018年5月22日):APP组中位OS 18.1个月 vs PP组13.6个月(分层HR=0.81,95%CI 0.64-1.03,P=0.0797)。
  • OS最终分析(2019年7月18日):APP组中位OS 17.5个月 vs PP组13.6个月(分层HR=0.86,95%CI 0.71-1.06,P=0.1546)。
  • 亚组分析中OS和PFS结果均倾向APP组优于PP组。
  • 3或4级治疗相关不良事件发生率APP组54.6%、PP组40.1%;5级治疗相关事件分别为3.8%和2.9%。

临床怎么用

  • 对于无EGFR/ALK突变的IV期非鳞NSCLC,APP方案可作为一线治疗选择之一,尤其注重PFS获益。
  • 治疗中需关注3-4级不良事件,APP组发生率高于单纯化疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We report the final results of the phase 3 IMpower132 study evaluating atezolizumab plus carboplatin or cisplatin plus pemetrexed (APP) in patients with nonsquamous NSCLC. METHODS: Chemotherapy-naive patients with stage IV nonsquamous NSCLC without sensitizing EGFR or ALK genetic alterations were randomized in a one-to-one ratio to receive four or six cycles of carboplatin or cisplatin plus pemetrexed (PP) or APP every 3 weeks, followed by maintenance therapy with atezolizumab plus pemetrexed or pemetrexed alone. Co-primary end points were overall survival (OS) and investigator-assessed progression-free survival (PFS). RESULTS: The intention-to-treat population included 578 patients (APP, n = 292; PP, n = 286). At the primary PFS analysis (May 22, 2018; median follow-up, 14.8 mo), APP exhibited significant PFS improvement versus PP (median = 7.6 versus 5.2 mo, stratified hazard ratio [HR] = 0.60, 95% confidence interval [CI]: 0.49-0.72, p < 0.0001). OS for the APP group was numerically better but not statistically significant at the interim (May 22, 2018; median = 18.1 versus 13.6 mo, stratified HR = 0.81, 95% CI: 0.64-1.03, p = 0.0797) and final analyses (July 18, 2019; median = 17.5 versus 13.6 mo; stratified HR = 0.86, 95% CI: 0.71-1.06, p = 0.1546). The OS and PFS results favored APP versus PP across subgroups. Grade 3 or 4 treatment-related adverse events occurred in 54.6% (APP) and 40.1% (PP) of patients; grade 5 treatment-related events occurred in 3.8% and 2.9%, respectively. CONCLUSIONS: IMpower132 met its co-primary PFS end point but not its co-primary OS end point, with numerical improvement for OS in the APP arm. APP had a manageable safety profile, with no new or unexpected safety signals identified.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Nishio M, Barlesi F, West H, et al. Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial. J Thorac Oncol. 2020. PMID: 33333328. doi:10.1016/j.jtho.2020.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。